Pharmaceutical Company CEO Developing $100 Alternative To EpiPen After 'Shameful' Price Hike
September 4, 2016
Mark Baum, CEO of Imprimis Pharmaceuticals who previously came out with a $1 alternative to Martin Shkreli's AIDS drug after 5000% price hike, is now going to take on Mylan and is plotting to offer a $100 EpiPen alternative.

Mark Baum / Imprimis Pharmceuticals
Baum believes the relentless EpiPen price hikes are "shameful" and plans to have a compounded version of the allergy treatment by the end of the year.
"I don't need to make $19 million a year," Baum said, referring to the big pay package Mylan's CEO Heather Bresch took home last year.
"Tonight when I go home I'm going to eat a nice piece of fish and the fish I eat isn't any better or worse than what she is going to eat."
Dogs Are Forced To Wear The Things They Steal — And It’s Hilarious
How A Silly 11-Second Song About Dr Pepper Changed Her Life Overnight
Senior Cat Labeled 'Sad And Scared' Finds Forever Home
She Could Have Kept Walking. Instead, She Stopped And Saved A Life
Family On Walk Finds Kitten Covered In Ice, Stuck To Plastic She Was Hiding Under
Newborn Calf Barely Survives Freezing Cold, Then Finds Warmth With Kids
'You're a Unicorn': The Dementia Caregiver Who Just Stunned The American Idol Judges
His Kids Wanted To Help With His Videos, So He Let Them Narrate — It’s The Cutest Thing
Meet Ella: She's 104, A WWII Veteran, And Swears By Peanut Butter
New Jersey Man Lets Robot Handle Snowstorm — Wakes Up To A Clear Driveway
Kid Knocks On Door To Ask If Their DOG Can Come Outside And Play
